6 от изследваните през изминалото денонощие проби са с положителен резултат за коронавирусна инфекция. Това съобщи главният държавен здравен инспектор доц. д-р Ангел Кунчев на редовния брифинг на Националния оперативен щаб.
2519 са общо лабораторно потвърдените случаи на новия коронавирус у нас. Излекуваните лица са 1090.
Случаите, регистрирани през последните 24 часа /общо 6/, са разпределени по области, както следва: Благоевград - 1; Пазарджик - 1; София – 4.
През последното денонощие не са констатирани нови случаи при лица-медицински специалисти.
Понеже хора като този по-горе на снимката и Киро Тефтера са си останали вероятно в някоя по-стара епоха / Семашкова/, предлагам на вниманието им какво се пише в литературата за серологичния тест на LaRoche: 99.8% специфичност и 100% достоверност за това дали 14 дни след положителен PCR тест пациента има имунитет срещу Covid-19: " About antibody testing An antibody test, also called a serology test, is used to determine whether a person might have gained immunity against a pathogen or not. The human body makes antibodies in response to many illnesses. In the current situation of the COVID-19 pandemic, antibody tests need to be able to specifically detect antibodies against SARS-CoV-2 with no cross-reactivity to other similar coronaviruses, which could generate a false positive result and thus wrongly indicate potential immunity. A false positive result happens when a person receives a positive test result, when they should have received a negative result. False positives are particularly critical when we do not know how many people in a given population have had COVID-19. As of 24 April 2020, no study has evaluated whether the presence of antibodies to SARS-CoV-2 confers immunity to subsequent infection by this virus in humans4. About Elecsys Anti-SARS-CoV-2 serology test Elecsys® Anti-SARS-CoV-2 is an immunoassay for the in-vitro qualitative detection of antibodies (including IgG) to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in human serum and plasma. Through a blood sample, the test, which is based on an in-solution double-antigen sandwich format, can detect antibodies to the new coronavirus causing COVID-19, which could signal whether a person has already been infected and potentially developed immunity to the virus. Based on the measurement of a total of 5272 samples, the Elecsys® Anti-SARS-CoV-2 assay has 99.81% specificity and shows no cross-reactivity to the four human coronaviruses causing common cold. This means it can lower the chance of false positives due to the detection of similar antibodies that may be present in an individual, but are specific for coronaviruses other than SARS-CoV-2. Elecsys® Anti-SARS-CoV-2 detected antibodies with 100% sensitivity in samples taken 14 days after a PCR-confirmed infection. The importance of specificity and sensitivity of a particular test will be dependent on its purpose and disease prevalence within a given population."